NCT00193531已完成2 期
Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Overall response
研究概览
简要总结
carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.
详细描述
Upon determination of eligibility, patients will be receive:
- Paclitaxel + Carboplatin + Etoposide
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Metastatic poorly differentiated neuroendocrine carcinoma
- •Unknown primary site
- •Able to perform activities of daily living with minimal assistance
- •Measurable or evaluable disease
- •Adequate bone marrow, liver functions and kidney function
- •No previous treatment with chemotherapy
- •Understand the nature of this study and give written informed consent.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Age < 18 years
- •Previous malignancy within five years
- •Women pregnant or lactating
- •Recent history of cardiovascular disease
- •Meningeal metastases
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Overall response
次要结局
- Overall toxicity
- Overall survival
- Time to progression
研究者
相似试验
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
招募中
2 期
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45
已完成
1 期
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)Solid TumorsNSCLCNCT01100931National Cancer Institute (NCI)42
已完成
2 期
Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.JPRN-UMIN000006767Shizuoka Cancer Center32
已完成
2 期
A Phase II Study of Carboplatin+weekly Paclitaxel+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer.JPRN-UMIN000003674Kochi University, School of Medicine, Department of Hematology and Respiratory Medicine43